

New structure to strengthen growth

The Gambro Group will develop into three independent companies. Gambro Renal Products will become the new Gambro. Gambro Healthcare and Gambro BCT will gradually become independent companies with formal Boards of Directors and independent governance processes. When the legal reorganization is completed Indap AB will serve as the holding entity of the three new companies. Peter Sjöstrand is elected new Chairman of Gambro AB. Thomas Glanzmann becomes the new CEO of Gambro AB, effective December 1, 2006.

The objective of the new structure is higher efficiency and increased transparency in order to strengthen competitiveness and promote growth. The three business areas are today in different stages of development and facing varying challenges and opportunities. By becoming stand-alone companies with three strong Boards of Directors the focus and speed of execution will increase and the companies will be in a better position to serve its customers through increased focus and stronger emphasis on innovation.

Indap AB, owned 51% by EQT and 49% by Investor AB, will be the holding entity of the three new companies. During a transition period, until Gambro BCT and Gambro Healthcare are legally reorganized, Gambro AB will handle governance issues for all three entities.

Peter Sjöstrand is elected new chairman of Gambro AB. **Thomas Glanzmann** becomes the new CEO of Gambro AB. He will join Gambro on a full time basis on December 1, 2006, but will gradually be introduced to the organization during November. Following these changes **Massimo Rossi** resigns as Chairman of the Board of Gambro AB and will become Chairman of the holding company Indap AB and **Jan Bruneheim** resigns as the CEO of Gambro AB and will become the CEO of Indap AB.

For further information please contact:

Paula Treutiger, phone +46-8-613 65 99, +46-733 66 65 99

Maria Långberg, phone +46-8-613 65 73, +46-705 13 65 73

Gambro is a global medical technology company with related services and has leading positions in renal care - services and products - and blood component technology. Gambro Renal Products develops and supplies hemodialysis, peritoneal dialysis, and acute renal and liver dialysis products, therapies and services. Gambro Healthcare is a provider of end-stage renal disease treatment and patient care. Gambro BCT develops and provides blood collection, apheresis and cell therapy products and services.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Jakobsgatan 6, PO Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com

Information about Peter Sjöstrand and Thomas Glanzmann

Peter Sjöstrand becomes the Chairman of Gambro AB. He has a broad and international experience from leading positions within the healthcare industry. He served many years as Executive Vice President and CFO in the Astra Group and was a member of the Astra Board of Directors from 1976-1993 (first as Secretary then as Deputy Member). Since 1993 he has been engaged in board assignments in both public and private companies in Europe and the US. He is a Medical Doctor from the Karolinska Institute in Stockholm and he holds a Bachelor of Science in Economy from the Stockholm School of Economics.

Thomas Glanzmann has been appointed the new CEO of Gambro AB. He has an extensive global general management background and a deep knowledge in the healthcare and consumer goods markets as well as a strong experience in building and growing businesses. He has held various positions at Baxter Healthcare Corporation from 1988-2004 including Senior Vice President and Corporate Officer and President of Baxter Bioscience. He is also an advisor to EQT and to the World Economic Forum. Currently he is the CEO of HemoCue AB, a global Swedish diagnostic company. He holds a Master of Business Administration from IMD, Switzerland, as well as a Bachelor of Political Science from Dartmouth College, U.S.